Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas

Esther Korpershoek*, Claudia K Stobbe*, Francien H van Nederveen, Ronald R de Krijger and Winand N M Dinjens

Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Room Ae304, PO Box 2040, 3000 CA Rotterdam, The Netherlands

(Correspondence should be addressed to E Korpershoek; Email: e.korpershoek.1@erasmusmc.nl)

*(E Korpershoek and C K Stobbe contributed equally to this work)

Abstract

Pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas (sPGLs) are catecholamine-producing tumors occurring in the context of hereditary tumor syndromes, with known germline mutations, and as sporadic tumors. The pathogenesis of sporadic PCC and sPGL is poorly understood, and little is known about intra-tumoral heterogeneity with respect to molecular aberrations. Since knowledge on intra-tumoral heterogeneity is important for understanding the pathogenesis of these tumors, we investigated 12 benign and 8 malignant PCCs and sPGLs for loss of heterozygosity (LOH) on DNA extracted from different regions of each tumor and from metastases. LOH markers were selected on chromosomal regions frequently deleted in PCC, including 1p, 3q, 3p, and 11p. Benign tumors were found to have less intra-tumoral heterogeneity (overall 8%) than malignant tumors (overall 23%), with the highest frequencies for chromosome 1p36 in the benign tumors (17%) and 1p13 and 3q24 in malignant tumors (both 38%). In addition, differences in LOH patterns were detected between paired primary malignant tumors, and their metastases and different LOH patterns were observed in bilateral PCC of a multiple endocrine neoplasia type 2 patient. We demonstrate that malignant PCC and sPGL have more intra-tumoral molecular heterogeneity than benign tumors, which suggests that benign and malignant PCC and sPGL have a different pathogenesis.

Endocrine-Related Cancer (2010) 17 653–662

Introduction

Pheochromocytomas (PCCs) are rare catecholamine-producing neuroendocrine tumors arising from chromaffin cells of the adrenal medulla. Extra-adrenal sympathetic paragangliomas (sPGLs) were previously known as extra-adrenal PCC. sPGLs are neuroendocrine tumors, mostly found in the abdomen, and usually produce catecholamines. PCC and sPGL are histologically indistinguishable, and share many clinical features, although sPGLs are more frequently malignant than PCC (Gimenez-Roqueplo et al. 2003, Lenders et al. 2005, Benn et al. 2006, Amar et al. 2007, Pacak et al. 2007).

Most PCCs are sporadic but up to 24% are associated with hereditary syndromes such as multiple endocrine neoplasia type 2 (MEN 2 caused by germline mutations in the proto-oncogene RET), Von Hippel–Lindau disease (VHL caused by germline mutations in the tumor suppressor gene VHL), PCC–PGL syndrome (caused by germline mutations in one of the tumor suppressor genes SDHB, SDHC, SDHD, or SDHAF2), and neurofibromatosis type 1 (NF1 caused by germline mutations in the NF1 tumor suppressor gene; Lenders 2005 #37, Bayley 2010 #208). The percentage of PCC associated with familial syndromes is higher than previously assumed, as several studies have demonstrated...

While loss of chromosome 1p is the most common genetic aberration reported in sporadic PCC (Dannenberg et al. 2000, Edstrom et al. 2000, Cascon et al. 2005, van Nederveen et al. 2009), particular genetic alterations have been demonstrated in syndrome-related PCC (Edstrom et al. 2000, Lui et al. 2002, Jarbo et al. 2005). Generally, MEN 2-related PCCs show loss of chromosomes 1p and 3q (Edstrom et al. 2000, Jarbo et al. 2005), SDHD-related PCCs and PGLs display loss of chromosome 11 (Hensen et al. 2004), and in NF1-related tumors, frequent loss of 1p and 17q is found (Edstrom et al. 2000, Bausch et al. 2007).

Few studies have demonstrated that sporadic PCCs have similar genetic aberrations as those found in syndrome-related tumors, such as loss of chromosomes 1p, 3p, 3q, 11p, and 11q (Dannenberg et al. 2000, Edstrom et al. 2000, Cascon et al. 2005, van Nederveen et al. 2009). Although the results at large of these studies are in agreement with each other, there are also differences. In a previous study, we have shown loss of chromosome 6 in 34% of sporadic PCC (Dannenberg et al. 2000), while this relatively high percentage was not found in other studies (Edstrom et al. 2000, Cascon et al. 2005). In addition, Cascon et al. (2005) reported loss of chromosome 8p in 62% of PCC, whereas this high percentage was not observed in other studies (Dannenberg et al. 2000, Edstrom et al. 2000, van Nederveen et al. 2009). These discrepancies could be due to geographical variations and hereditary background of the patients, differences in methods, but can also be the effect of intra-tumoral molecular heterogeneity.

Intra-tumoral molecular heterogeneity has been demonstrated in many different tumors, such as in renal tumors (Nenning et al. 1997), head and neck squamous cell carcinomas (Califano et al. 1996), lung tumors (Blackhall et al. 2004), cervical cancer (Bachtiary et al. 2006), and meningiomas (Sayagues et al. 2004), but has been poorly investigated in PCC. Jarbo et al. (2005) reported that the ratios of chromosome 22q loss in some PCC samples were higher than expected for a single allele ratio, and suggested this could be due to intra-tumoral heterogeneity. Diaz-Cano et al. (2000) investigated heterogeneity of sporadic and MEN 2-related PCC and adrenal medullary hyperplasia (AMH) nodules, by determining the methylation patterns of the androgen receptor (AR) gene, localized on the X-chromosome. All informative AMH showed concordant inactivation of the same alleles in different nodules from the same adrenal gland, suggesting that these AMH nodules arose from a common progenitor and are clonally related proliferations. In addition, the authors reported that a high percentage of sporadic PCC, benign as well as malignant, also show intra-tumoral concordant inactivation of the same AR alleles, and therefore, PCCs were considered monoclonal in origin. Apart from this study, no reports exist about intra-tumoral heterogeneity of PCC on the molecular level.

PCC and sPGL are, as most other tumors, considered as monoclonal proliferations originating from one transformed cell. Transformation of a normal cell into a tumor cell is caused by the accumulation of mutations, among others in oncogenes and tumor suppressor genes. This implies that mutations occurring early in tumorigenesis are present in each individual tumor cell, whereas DNA aberrations that occurred later, during tumor growth, can be present only in a subpopulation of tumor cells. When investigating multiple, macroscopically separated, intra-tumoral regions for DNA aberrations, homogeneity of mutations indicates early aberrations, whereas heterogeneity points to later occurrence.

Molecular heterogeneity is important for elucidating the molecular pathogenesis of PCC. In addition, intra-tumoral heterogeneity is important for the interpretation of loss of heterozygosity (LOH) and comparative genomic hybridization (CGH) results in general. Furthermore, heterogeneity of PCC has never been thoroughly investigated. Therefore, we systematically investigated LOH in four macroscopically separated parts within each of 12 benign tumors (11 PCCs and 1 sPGL) from 11 patients, and 8 malignant tumors (seven PCCs and one sPGL) and 8 metastases from eight patients.

Materials and methods

Patients

Nineteen patients with PCC or sPGL were selected, of whom 11 had benign tumors (ten PCCs and one sPGL) and 8 had malignant tumors (seven PCCs and one sPGL). All eight patients with malignant tumors had distant metastases verified by histology. The tumors were retrieved from the archives of the Departments of Pathology of the Erasmus MC, University Medical Center, Rotterdam (15 cases), Maasstad Hospital, Rotterdam (1 case), University Medical Center Utrecht (1 case), Albert Schweitzer Hospital Dordrecht (1 case), and PAMM foundation, Veldhoven (1 case).
The Netherlands. The tumors were anonymously used according to the code for adequate secondary use of tissue, code of conduct: ‘Proper Secondary Use of Human Tissue’ established by the Dutch Federation of Medical Scientific Societies (http://www.federa.org).

The benign series included six sporadic cases and five patients with syndrome-related tumors: two patients with NF1 (clinically determined) and one patient with MEN 2 (*RET* germline mutation Cys634Arg) of whom both tumors (left and right adrenal) were investigated and two patients with the PCC–PGL syndrome (*SDHD* germline mutation Asp92Tyr). One sporadic patient with a benign PCC was also diagnosed with a clear cell renal cell carcinoma (RCC). Although an RCC can be a feature of VHL disease, genetic analysis did not reveal a germline *VHL* mutation. The malignant series was comprised of seven sporadic PCCs, one PCC–PGL syndrome-related sPGL (*SDHD* germline mutation Asp92Tyr), and seven metastases.

The mean patient age at diagnosis was 46 years (range 16–76 years) and 54 years (range 36–63 years) for the benign and malignant series respectively. The mean primary tumor diameter was 3.9 cm (range 0.9–6 cm) for the benign series and 8.7 cm (range 0.7–15 cm) for the malignant series. Patient characteristics and clinical data are summarized in Table 1.

DNA preparation

Forty-seven tumor DNA samples were isolated from four macroscopically separated areas within the paraffin-embedded tumors of 11 patients, and from three areas within the tumor of one patient with benign tumors. Matching normal DNA was isolated from paraffin-embedded healthy tissues of other unaffected organs or normal tissue surrounding the tumor. For the malignant tumors, an additional DNA sample was isolated from metastatic tissue (Fig. 1). In total, 37 tumor DNA samples were isolated from the PCC or sPGL, and metastases of the patients with malignant tumors. From patient 18, only one small primary tumor and two metastases were available for investigation, of which three tumor DNA samples were isolated. Furthermore, of patient 19, only the primary tumor was available and used to isolate four tumor DNA samples.

DNA was isolated using the D-5000 Puregene DNA Isolation kit (Gentra Systems, Minneapolis, MN, USA) according to the manufacturer’s recommendations. Before and after DNA extraction, hematoxylin and eosin staining of each section was performed to confirm the percentage of tumor cells in the isolated samples, which was above 80% for proper LOH analysis.

Table 1 Clinical data of pheochromocytoma and extra-adrenal sympathetic paraganglioma patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Other features</th>
<th>Location primary tumor</th>
<th>Tumor diameter (cm)</th>
<th>Tumor weight (g)</th>
<th>Location metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign</td>
<td>1</td>
<td>F</td>
<td>76</td>
<td>–</td>
<td>a</td>
<td>4</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>F</td>
<td>39</td>
<td>–</td>
<td>a</td>
<td>6</td>
<td>54.3</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>F</td>
<td>55</td>
<td>–</td>
<td>ea</td>
<td>6</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>M</td>
<td>16</td>
<td>PCC–PGL syndrome</td>
<td>a</td>
<td>4.5</td>
<td>68.1</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>F</td>
<td>31</td>
<td>PCC–PGL syndrome</td>
<td>a</td>
<td>u</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>M</td>
<td>29</td>
<td>NF1</td>
<td>a</td>
<td>3</td>
<td>18.8</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>M</td>
<td>65</td>
<td>–</td>
<td>a</td>
<td>4.5</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>F</td>
<td>46</td>
<td>Renal cell carcinoma</td>
<td>a</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>M</td>
<td>52</td>
<td>NF1</td>
<td>a</td>
<td>u</td>
<td>u</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>u</td>
<td>–</td>
<td>–</td>
<td>a</td>
<td>4</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>F</td>
<td>51</td>
<td>MEN2A – bilateral</td>
<td>a</td>
<td>4/0.9</td>
<td>23/19</td>
</tr>
<tr>
<td>Malignant</td>
<td>12</td>
<td>M</td>
<td>62</td>
<td>–</td>
<td>a</td>
<td>5</td>
<td>176</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>F</td>
<td>63</td>
<td>–</td>
<td>a</td>
<td>10</td>
<td>u</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>F</td>
<td>61</td>
<td>–</td>
<td>a</td>
<td>12</td>
<td>u</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>M</td>
<td>42</td>
<td>–</td>
<td>a</td>
<td>8.5</td>
<td>166</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>M</td>
<td>61</td>
<td>–</td>
<td>a</td>
<td>u</td>
<td>u</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>F</td>
<td>43</td>
<td>–</td>
<td>a</td>
<td>0.7</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>M</td>
<td>36</td>
<td>–</td>
<td>a</td>
<td>15</td>
<td>u</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>M</td>
<td>62</td>
<td>PCC–PGL syndrome</td>
<td>ea</td>
<td>10</td>
<td>264</td>
</tr>
</tbody>
</table>

F = female, M = male, a = adrenal, ea = extra-adrenal, u = unknown.
LOH analysis was performed with two different methods, using ten markers on five loci, which have been reported to be frequently lost in PCC. The markers selected were localized on chromosomes 1p13 (D1S252 and D1S2881), 1p36 (D1S2885 and D1S234), 3p13 (D3S3681 and D3S3551), 3q24 (D3S1569 and D3S3694), and 11p13 (D11S4083 and D11S4203).

The first PCR method was carried out using 32P-dATP (Amersham) and run on a denaturing 6% polyacrylamide gel (Fluka). After electrophoresis for 2 h at 65 W, the gels were dried and exposed to X-ray films. The results were confirmed by a previously described PCR method (Gaal et al. 2009), using fluorescence-labeled primers (Invitrogen) and ABI 3130-XL genetic analyzer (Applied Biosystems, Foster City, CA, USA) for analysis. The results of both methods were analyzed by two independent investigators (W D and E K).

Cases were classified as informative when two alleles were found in normal DNA. When relative intensities of allelic signals observed in tumor DNA clearly differed from those in normal DNA, this was considered as loss. LOH was further categorized as loss of the lower (or smaller) or upper (or larger) allele. A tumor was considered genetically heterogeneous when LOH was present in at least one sample but not in all the samples of the same tumor or if the samples differed in loss of a lower or upper allele.

Results

LOH frequencies

Results of the LOH analysis for each marker in the benign and malignant tumors are shown in Figures 2 and 3 respectively. The data are also summarized for both tumor groups in Table 2. PCR with a second marker was only performed if the patient was not informative for the first marker for the investigated locus.

Most frequent losses were found for chromosome 1p occurring in up to 75% (considering 1p13) for both benign and malignant tumors. Loss of chromosome 3q occurred in 45% (5/11) of the benign tumors, and in 63% (5/8) of the malignant tumors. Loss of chromosome 3p was found in 25% (3/12) of the benign tumors and in 38% (3/8) of the malignant tumors. In addition, loss of chromosome 11p was seen in 50% (6/12) of the benign tumors and in 17% (1/6) of the malignant tumors. One PCC (patient 16) of the malignant series did not reveal any LOH.

Notably, two malignant tumors showed homogeneous LOH patterns in the different primary tumor samples, but no LOH in the DNA derived from the metastasis. This occurred in patient 12 for chromosome 3p12 and in patient 17 for chromosome 1p13. The overall LOH frequency did not differ between the benign (44%) and malignant (47%) tumors.
Figure 2 Loss of heterozygosity (LOH) results of the benign pheochromocytomas and extra-adrenal sympathetic paragangliomas. □, no LOH; ■, loss of upper allele; □, loss of lower allele; NI, not informative; x, no data; –, no tissue available; T1–T4, tumor DNA samples from different areas of the tumor.
Heterogeneity frequencies

A summary of the intra-tumoral heterogeneity results is shown in Table 2. An example of heterogeneity is illustrated in Fig. 4. Tumor DNAs were isolated from macroscopically different parts of the tumor. There was no correlation between histology and molecular heterogeneity, as these macroscopically different parts were histologically similar (Fig. 1). Intra-tumoral heterogeneity was found in 42% (5/12) and 75% (6/8) of the benign and malignant tumors respectively.
chromosomal regions reported to have high frequencies of LOH in PCC (chromosome 1p13 and chromosome 3q), there was more intra-tumoral heterogeneity present in the malignant tumors (37.5% for both regions) compared with the benign tumors (8.3% for both regions). In contrast, chromosome 11p showed no intra-tumoral heterogeneity in the malignant tumors, compared with 16.7% in the benign tumors. Additionally, the average frequency of intra-tumoral heterogeneity of the malignant tumors (22.5%) was higher than of the benign tumors (10.2%).

**Syndrome-related PCC LOH results**

Remarkably, both PCCs of the MEN 2A patient (patient 11) revealed different aberrations in chromosomal region 1p13: in both tumors, opposing 1p13 allele loss was observed homogeneously in all tumor samples of each tumor (Fig. 2). In addition, tumor A of patient 11 showed homogeneous loss of chromosome 3q24 in all tumor samples, whereas the contralateral tumor B did not display 3q24 LOH in any of the tumor DNA samples (Fig. 2).

Three patients had PCC–PGL syndrome caused by a germline SDHD mutation (localized on chromosome 11). The PCC of two PCC–PGL syndrome patients (Fig. 2, cases 4 and 5) showed LOH of chromosome 11p in all tumor samples; the sPGL of the other patient (Fig. 3, case 19) was not informative for the chromosome 11 marker. In addition, two patients had NF1-related PCC (characterized by loss of chromosome 1p36), which both displayed homogeneous loss of 1p36 in all samples (Fig. 2, cases 6 and 9).

**Discussion**

The knowledge of intra-tumoral molecular heterogeneity in PCC and sPGL is important for understanding the pathogenesis of these tumors. In addition, heterogeneity can have consequences for interpretation of molecular data. Therefore, we determined the intra-tumoral molecular heterogeneity in a series of 12 benign tumors (11 PCC and 1 sPGL) and 8 malignant tumors (seven PCC and one sPGL) by LOH analysis in different areas of the tumors. Molecular intra-tumoral heterogeneity within tumors has been reported in 55% of meningiomas (Sayagues et al. 2004), 45% of renal tumors (Nenning et al. 1997), 2.7% of cervical cancer (Bachtiary et al. 2006), and in 8.8% of PCC (Diaz-Cano et al. 2000). It is important to emphasize that these frequencies show extreme variation because 1) the amount of markers or probes used per study are different. The more probes being used, the more heterogeneity is found. In case of Bachtiary et al. (2006) who used expression arrays to investigate a series of cervical cancer, a ratio of two internal controls was used to determine intra-tumoral heterogeneity. A ratio of more than 0.90 was considered as high heterogeneity (2.7%), whereas <0.10 was regarded as extreme low heterogeneity (2.2%). In contrast, ratios in between had a global lower heterogeneity, so the frequency of heterogeneity will be up to 100%; 2) other studies used only few markers or probes (Nenning et al. 1997, Diaz-Cano et al. 2000, Sayagues et al. 2004), whose genomic location is of great importance. When probes are chosen in genomic areas that are lost early in pathogenesis, the tumors will show no or little intra-tumoral heterogeneity, whereas probes on chromosomes that are altered later in tumorigenesis will result in high frequencies of heterogeneity; and 3) PCC can occur in several syndromes, such as the MEN 2 syndrome, VHL disease, or the PCC–PGL syndrome. The PCCs in these syndromes have different alterations that occur early in the pathogenesis, such as loss of chromosomes 1p and 3q in MEN 2-related PCC and loss of chromosome 11 in SDHD-related PCC. This could explain why SDHD-related PCCs show heterogeneity for markers on chromosome 1p, and MEN 2-related PCCs show heterogeneity for markers on chromosome 11q in our study. LOH of these chromosomes was most likely a late event in the pathogenesis in both PCCs.

Our LOH results, showing heterogeneity in only 1 of the 12 benign tumors, are in concurrence with literature reports since chromosomes 1p13 and 3q are reported as early aberrations in benign sporadic and MEN 2A-related PCC (Dannenberg et al. 2000, van Nederveen et al. 2009) and loss of chromosome 1p36 is the most

<table>
<thead>
<tr>
<th>Benign tumors</th>
<th>1p13</th>
<th>1p36</th>
<th>3q</th>
<th>3p</th>
<th>11p</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOH</td>
<td>9/12 (75)</td>
<td>8/12 (67)</td>
<td>5/11 (45)</td>
<td>3/12 (25)</td>
<td>6/12 (50)</td>
</tr>
<tr>
<td>Intra-tumoral heterogeneity</td>
<td>1/12 (8)</td>
<td>2/12 (17)</td>
<td>1/11 (9)</td>
<td>0/12 (0)</td>
<td>2/12 (17)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Malignant tumors</th>
<th>1p13</th>
<th>1p36</th>
<th>3q</th>
<th>3p</th>
<th>11p</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOH</td>
<td>6/8 (75)</td>
<td>5/8 (63)</td>
<td>5/8 (63)</td>
<td>3/8 (38)</td>
<td>1/6 (17)</td>
</tr>
<tr>
<td>Intra-tumoral heterogeneity</td>
<td>3/8 (38)</td>
<td>2/8 (25)</td>
<td>3/8 (38)</td>
<td>1/8 (13)</td>
<td>0/6 (0)</td>
</tr>
</tbody>
</table>

Numbers (in brackets percentages) represent LOH or heterogeneity observed in patients/total patients that were informative.
frequent molecular alteration in NF1-related PCC (Edstrom et al. 2000, Bausch et al. 2007). The tumor showing heterogeneous loss of chromosomes 1p13 and 3q24 was an SDHD-related PCC, with consistent identical LOH of 11p in all tumor samples, indicating monoclonal origin. SDHD-related tumors are characterized by bi-allelic inactivation of the SDHD gene: the combination of a germline mutation in the SDHD gene and loss of the remaining wild-type allele (11q23). Therefore, in SDHD-related tumors, loss of the wild-type chromosome 11q allele is most likely the tumor-initiating event preceding loss of chromosome 1p.

MEN 2A-related PCCs are characterized by loss of chromosomes 1p and 3q (Edstrom et al. 2000, Jarbo et al. 2005, van Nederveen et al. 2009). Our study included one MEN 2A patient with bilateral benign PCC. In both tumors, homogeneous loss of chromosome 1p in all tumor samples was found. However, both tumors showed loss of opposing 1p alleles. In addition, loss of chromosome 3q was seen in only one of the bilateral PCC. The PCC of this MEN 2A patient showed inter-tumoral heterogeneity, indicating that these tumors occurred independently.

It is generally accepted that neoplastic cells harbor clonal molecular aberrations and normal cells do not. Tumors, like PCC and sPGL, are composed of neoplastic and normal cells. Consequently, DNA isolated from a part of PCC or sPGL is composed of DNA of neoplastic cells and normal cells. With LOH analyses, tumor and corresponding normal DNA are compared, so information about loss of DNA within the tumor sample can be obtained, but also information about which allele – or microsatellite marker – is lost. In this study, most tumor DNAs were isolated from parts that consisted of high percentages neoplastic cells, since histology of the tumor blocks was checked before and after DNA isolation. In addition, admixture of high percentage of normal cells would mask the detection of aberrations. In our study, all 48 DNA samples of the benign tumor series and in 29 of 37 DNA samples from the malignant series unequivocal LOH were observed with at least one LOH marker. This indicates that these DNA samples were all derived from a homogeneous tumor cell population with little admixture of normal – endothelial or stromal – cells. However, five DNA samples from patient 16 and in three of four samples from patient 19 did not show LOH with four and six informative markers respectively. This is probably due to the absence of genomic alterations at these loci, but to confirm this more markers should be tested.

Molecular heterogeneity could also be due to technical artifacts. However, although PCR-based assays can vary in sensitivity between loci, sensitivity is unlikely to differ between samples if the same primers and PCR conditions were used. The sensitivity of detecting LOH is based on the PCR sensitivity (is a PCR product generated or not), the size difference

![Figure 4](image)
malignant tumors in our study suggests a different increased frequency of molecular heterogeneity in different parts of the tumor. So, the proliferation with different genetic backgrounds. Therefore, malignant PCC could also demonstrate molecular heterogeneity at a higher frequency. However, it is very likely that molecular aberrations occurred early in tumorigenesis and have resulted in a pronounced selective growth advantage will be homogeneously present in the tumors. In addition, we demonstrated that intra-tumoral molecular heterogeneity occurred more often in malignant tumors than in benign tumors, suggesting that malignant and benign PCCs evolve along different tumorigenic processes. These findings suggest that benign and malignant PCCs can be different entities, whereby malignant tumors can be malignant from the onset and do not necessarily evolve from benign tumors.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


